Captopril and spleen size in thalassemia

Not Applicable

Recruiting

• Conditions: thalassemia.; Beta thalassemia; D56.1

• Registration Number: IRCT20121117011491N2
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Accept to participate
Major or Intermedia thalassemia patient who is transfusion dependent and has splenomegaly
No Other Hematologic problem except Thalassemia

Exclusion Criteria

Neurological problem or Cr more than 1.5 mg/dl
Hx of Drug reaction to captopril or any contraindication for ACE inhibitor
Hypotension ( Blood pressure less than 80 mmhg )
Neutropenia or thrombocytopenia
partial or total Splenectomy
Jak inhibitor usage

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Spleen size. Timepoint: 3 months interval till 9 months. Method of measurement: Sonographic measurement.;Hemoglobin level. Timepoint: 3 month interval till 9 month. Method of measurement: CBC.;Need for Blood Transfusion. Timepoint: Changes during 9 month. Method of measurement: Interval of Transfusion by month.

Secondary Outcome Measures

Name	Time	Method
Erythropoietin level. Timepoint: at the beginning and end of the Study. Method of measurement: Quantitative Chemiluminescent Immunoassay.